- Home
- SPCE vs CKPT Comparison
SPCE vs CKPT Comparison
Compare SPCE & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- CKPT
- Stock Information
- Founded
- SPCE 2017
- CKPT 2014
- Country
- SPCE United States
- CKPT United States
- Employees
- SPCE N/A
- CKPT N/A
- Industry
- SPCE Transportation Services
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- CKPT Health Care
- Exchange
- SPCE Nasdaq
- CKPT Nasdaq
- Market Cap
- SPCE 187.1M
- CKPT 172.4M
- IPO Year
- SPCE N/A
- CKPT 2017
- Fundamental
- Price
- SPCE $2.82
- CKPT $4.04
- Analyst Decision
- SPCE Hold
- CKPT Buy
- Analyst Count
- SPCE 5
- CKPT 3
- Target Price
- SPCE $19.85
- CKPT $4.33
- AVG Volume (30 Days)
- SPCE 2.3M
- CKPT 5.7M
- Earning Date
- SPCE 05-06-2025
- CKPT 03-28-2025
- Dividend Yield
- SPCE N/A
- CKPT N/A
- EPS Growth
- SPCE N/A
- CKPT N/A
- EPS
- SPCE N/A
- CKPT N/A
- Revenue
- SPCE $7,036,000.00
- CKPT $41,000.00
- Revenue This Year
- SPCE N/A
- CKPT $102,182.93
- Revenue Next Year
- SPCE $8,942.38
- CKPT $351.71
- P/E Ratio
- SPCE N/A
- CKPT N/A
- Revenue Growth
- SPCE 3.47
- CKPT N/A
- 52 Week Low
- SPCE $2.72
- CKPT $1.38
- 52 Week High
- SPCE $28.20
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- SPCE 32.07
- CKPT 65.90
- Support Level
- SPCE $2.85
- CKPT $4.01
- Resistance Level
- SPCE $4.44
- CKPT $4.07
- Average True Range (ATR)
- SPCE 0.33
- CKPT 0.03
- MACD
- SPCE -0.05
- CKPT -0.00
- Stochastic Oscillator
- SPCE 5.52
- CKPT 70.00
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.